I’m behind 100% with the one that brought us to the dance.
This isn't a dance. It is a question of science. Leronlimab's trials have been a failure. Both the CD10 and CD12 trials had a couple of good data points that represented tiny portions of the trials. Loyalty is great trait to possess when you go to a dance with someone. Loyalty is a horrible trait for a biotech investor.